Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Walter Milano, Valeria De Biasio, Walter Di Munzio, Giuseppina Foggia and Anna Capasso*

DOI: 10.2174/1871530320666200515112853

DownloadDownload PDF Flyer Cite As
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy

Page: [1232 - 1243] Pages: 12

  • * (Excluding Mailing and Handling)

Abstract

Background: The increase in global obesity rates over the past three decades has been remarkable, a true epidemic, both in developed and in developing countries. The projections, based on current trends, suggest an increase in the prevalence of obesity at 60% in adult men, 40% in adult women and 25% in children in 2050. Given the limitations of lifestyle and surgery interventions bariatric, drug therapy approaches for the treatment of obesity, therefore become important options.

Aim: The purpose of this review is a review of the literature, based on research on MEDLINE until 2019, on the possible pharmacological options in the treatment of obesity.

Results: Currently, the FDA has approved several molecules for the treatment of obesity, both in monotherapy and in combination. Pharmacological monotherapies focus mainly on a single protein target and include orlistat, lorcaserin and liraglutide while the combination molecules propose a multitarget approach and include phentermine/topiramate and naltrexone/bupropion. All the approved drugs showed, in the different studies, a weight reduction of at least 5%, compared to placebo, in 52 weeks of observation. Phentermine-topiramate and liraglutide have been associated with the highest probability of at least 5% weight loss. Liraglutide and naltrexone-bupropion had the lowest rates of therapy discontinuation due to adverse events.

Conclusion: The drugs, associated with the standard diet and/or exercise protocols, represent a good therapeutic opportunity to allow not only weight loss but also to reduce the risk of developing diseases caused by obesity, particularly cardiovascular diseases, and to maintain the set objectives over time. However, future research on the pharmacological treatment of obesity should encourage greater personalization of therapy, given the differences in safety, efficacy and response to therapy, in the different subpopulations of patients with obesity.

Keywords: Obesity, pharmacotherapy, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate and liraglutide.

Graphical Abstract

[1]
World Health Organization Report of the commission on Ending childhood obesity implementation plan: executive summary, 2017.
[2]
World Health Organization Fact Sheet N°311., 2015.
[3]
Blundell, J.E.; Baker, J.L.; Boyland, E.; Blaak, E.; Charzewska, J.; de Henauw, S.; Frühbeck, G.; Gonzalez-Gross, M.; Hebebrand, J.; Holm, L.; Kriaucioniene, V.; Lissner, L.; Oppert, J.M.; Schindler, K.; Silva, A.L.; Woodward, E. Variations in the prevalence of obesity among european countries, and a consideration of possible causes. Obes. Facts, 2017, 10(1), 25-37.
[http://dx.doi.org/10.1159/000455952] [PMID: 28190010]
[4]
The Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: Individual participant-data meta-analysis of 239 prospective studies in four continents. Lancet, 2016, 388(10046), 776-786.
[5]
Afshin, A.; Forouzanfar, M.H.; Reitsma, M.B.; Sur, P.; Estep, K.; Lee, A.; Marczak, L.; Mokdad, A.H.; Moradi-Lakeh, M.; Naghavi, M.; Salama, J.S.; Vos, T.; Abate, K.H.; Abbafati, C.; Ahmed, M.B.; Al-Aly, Z.; Alkerwi, A.; Al-Raddadi, R.; Amare, A.T.; Amberbir, A.; Amegah, A.K.; Amini, E.; Amrock, S.M.; Anjana, R.M.; Ärnlöv, J.; Asayesh, H.; Banerjee, A.; Barac, A.; Baye, E.; Bennett, D.A.; Beyene, A.S.; Biadgilign, S.; Biryukov, S.; Bjertness, E.; Boneya, D.J.; Campos-Nonato, I.; Carrero, J.J.; Cecilio, P.; Cercy, K.; Ciobanu, L.G.; Cornaby, L.; Damtew, S.A.; Dandona, L.; Dandona, R.; Dharmaratne, S.D.; Duncan, B.B.; Eshrati, B.; Esteghamati, A.; Feigin, V.L.; Fernandes, J.C.; Fürst, T.; Gebrehiwot, T.T.; Gold, A.; Gona, P.N.; Goto, A.; Habtewold, T.D.; Hadush, K.T.; Hafezi-Nejad, N.; Hay, S.I.; Horino, M.; Islami, F.; Kamal, R.; Kasaeian, A.; Katikireddi, S.V.; Kengne, A.P.; Kesavachandran, C.N.; Khader, Y.S.; Khang, Y.H.; Khubchandani, J.; Kim, D.; Kim, Y.J.; Kinfu, Y.; Kosen, S.; Ku, T.; Defo, B.K.; Kumar, G.A.; Larson, H.J.; Leinsalu, M.; Liang, X.; Lim, S.S.; Liu, P.; Lopez, A.D.; Lozano, R.; Majeed, A.; Malekzadeh, R.; Malta, D.C.; Mazidi, M.; McAlinden, C.; McGarvey, S.T.; Mengistu, D.T.; Mensah, G.A.; Mensink, G.B.M.; Mezgebe, H.B.; Mirrakhimov, E.M.; Mueller, U.O.; Noubiap, J.J.; Obermeyer, C.M.; Ogbo, F.A.; Owolabi, M.O.; Patton, G.C.; Pourmalek, F.; Qorbani, M.; Rafay, A.; Rai, R.K.; Ranabhat, C.L.; Reinig, N.; Safiri, S.; Salomon, J.A.; Sanabria, J.R.; Santos, I.S.; Sartorius, B.; Sawhney, M.; Schmidhuber, J.; Schutte, A.E.; Schmidt, M.I.; Sepanlou, S.G.; Shamsizadeh, M.; Sheikhbahaei, S.; Shin, M.J.; Shiri, R.; Shiue, I.; Roba, H.S.; Silva, D.A.S.; Silverberg, J.I.; Singh, J.A.; Stranges, S.; Swaminathan, S.; Tabarés-Seisdedos, R.; Tadese, F.; Tedla, B.A.; Tegegne, B.S.; Terkawi, A.S.; Thakur, J.S.; Tonelli, M.; Topor-Madry, R.; Tyrovolas, S.; Ukwaja, K.N.; Uthman, O.A.; Vaezghasemi, M.; Vasankari, T.; Vlassov, V.V.; Vollset, S.E.; Weiderpass, E.; Werdecker, A.; Wesana, J.; Westerman, R.; Yano, Y.; Yonemoto, N.; Yonga, G.; Zaidi, Z.; Zenebe, Z.M.; Zipkin, B.; Murray, C.J.L. GBD 2015 Obesity Collaborators. GBD (2015) Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med., 2017, 377(1), 13-27.
[http://dx.doi.org/10.1056/NEJMoa1614362] [PMID: 28604169]
[6]
Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; Mullany, E.C.; Biryukov, S.; Abbafati, C.; Abera, S.F.; Abraham, J.P.; Abu-Rmeileh, N.M.; Achoki, T.; AlBuhairan, F.S.; Alemu, Z.A.; Alfonso, R.; Ali, M.K.; Ali, R.; Guzman, N.A.; Ammar, W.; Anwari, P.; Banerjee, A.; Barquera, S.; Basu, S.; Bennett, D.A.; Bhutta, Z.; Blore, J.; Cabral, N.; Nonato, I.C.; Chang, J.C.; Chowdhury, R.; Courville, K.J.; Criqui, M.H.; Cundiff, D.K.; Dabhadkar, K.C.; Dandona, L.; Davis, A.; Dayama, A.; Dharmaratne, S.D.; Ding, E.L.; Durrani, A.M.; Esteghamati, A.; Farzadfar, F.; Fay, D.F.; Feigin, V.L.; Flaxman, A.; Forouzanfar, M.H.; Goto, A.; Green, M.A.; Gupta, R.; Hafezi-Nejad, N.; Hankey, G.J.; Harewood, H.C.; Havmoeller, R.; Hay, S.; Hernandez, L.; Husseini, A.; Idrisov, B.T.; Ikeda, N.; Islami, F.; Jahangir, E.; Jassal, S.K.; Jee, S.H.; Jeffreys, M.; Jonas, J.B.; Kabagambe, E.K.; Khalifa, S.E.; Kengne, A.P.; Khader, Y.S.; Khang, Y.H.; Kim, D.; Kimokoti, R.W.; Kinge, J.M.; Kokubo, Y.; Kosen, S.; Kwan, G.; Lai, T.; Leinsalu, M.; Li, Y.; Liang, X.; Liu, S.; Logroscino, G.; Lotufo, P.A.; Lu, Y.; Ma, J.; Mainoo, N.K.; Mensah, G.A.; Merriman, T.R.; Mokdad, A.H.; Moschandreas, J.; Naghavi, M.; Naheed, A.; Nand, D.; Narayan, K.M.; Nelson, E.L.; Neuhouser, M.L.; Nisar, M.I.; Ohkubo, T.; Oti, S.O.; Pedroza, A.; Prabhakaran, D.; Roy, N.; Sampson, U.; Seo, H.; Sepanlou, S.G.; Shibuya, K.; Shiri, R.; Shiue, I.; Singh, G.M.; Singh, J.A.; Skirbekk, V.; Stapelberg, N.J.; Sturua, L.; Sykes, B.L.; Tobias, M.; Tran, B.X.; Trasande, L.; Toyoshima, H.; van de Vijver, S.; Vasankari, T.J.; Veerman, J.L.; Velasquez-Melendez, G.; Vlassov, V.V.; Vollset, S.E.; Vos, T.; Wang, C.; Wang, X.; Weiderpass, E.; Werdecker, A.; Wright, J.L.; Yang, Y.C.; Yatsuya, H.; Yoon, J.; Yoon, S.J.; Zhao, Y.; Zhou, M.; Zhu, S.; Lopez, A.D.; Murray, C.J.; Gakidou, E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the global burden of disease study 2013. Lancet, 2014, 384(9945), 766-781.
[http://dx.doi.org/10.1016/S0140-6736(14)60460-8] [PMID: 24880830]
[7]
Pereira, M.A. Long-term body mass index and mortality in the framingham heart study. Unpacking an Ounce of Prevention. JAMA Netw. Open, 2018, 1(7), e184585.
[8]
Hanfei, Xu M.S.; Adrienne Cupples, L.; Stokes, A.; Ching-Ti, Liu. Association of obesity with mortality over 24 years of weight history findings from the framingham heart study. JAMA Netw. Open, 2018, 1(7), e184587.
[9]
NCHS. Health, United States, 2012 with special feature one mergency care; Hyattsville, Maryland; , 2013.
[10]
Ogden, C.L.; Carroll, M.D.; Curtin, L.R.; McDowell, M.A.; Tabak, C.J.; Flegal, K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA, 2006, 295(13), 1549-1555.
[http://dx.doi.org/10.1001/jama.295.13.1549] [PMID: 16595758]
[11]
Neeland, I.J.; Poirier, P.; Després, J-P. Cardiovascular and metabolic heterogeneity of obesity: Clinical challenges and implications for management. Circulation, 2018, 137(13), 1391-1406.
[PMID: 29581366]
[12]
Flegal, K.M.; Graubard, B.I.; Williamson, D.F.; Gail, M.H. Excess deaths associated with underweight, overweight, and obesity. JAMA, 2005, 293(15), 1861-1867.
[http://dx.doi.org/10.1001/jama.293.15.1861] [PMID: 15840860]
[13]
Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. Lancet, 2005, 365(9468), 1415-1428.
[http://dx.doi.org/10.1016/S0140-6736(05)66378-7] [PMID: 15836891]
[14]
Colditz, G.A.; Willett, W.C.; Stampfer, M.J.; Manson, J.E.; Hennekens, C.H.; Arky, R.A.; Speizer, F.E. Weight as a risk factor for clinical diabetes in women. Am. J. Epidemiol., 1990, 132(3), 501-513.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a115686] [PMID: 2389754]
[15]
Kurth, T.; Gaziano, J.M.; Berger, K.; Kase, C.S.; Rexrode, K.M.; Cook, N.R.; Buring, J.E.; Manson, J.E. Body mass index and the risk of stroke in men. Arch. Intern. Med., 2002, 162(22), 2557-2562.
[http://dx.doi.org/10.1001/archinte.162.22.2557] [PMID: 12456227]
[16]
Calle, E.E.; Rodriguez, C.; Walker-Thurmond, K.; Thun, M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 2003, 348(17), 1625-1638.
[http://dx.doi.org/10.1056/NEJMoa021423] [PMID: 12711737]
[17]
Petry, N.M.; Barry, D.; Pietrzak, R.H.; Wagner, J.A. Overweight and obesity are associated with psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom. Med., 2008, 70(3), 288-297.
[http://dx.doi.org/10.1097/PSY.0b013e3181651651] [PMID: 18378873]
[18]
GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, 393, 1958-1972.
[19]
Public Health England. ; Making the case for tackling obesity why invest?, 2015.February. Available at: https://khub.net/documents/31798783/32184747/Making+the+case+for+tackling+obesity+-+why+invest+-+supporting+references.pdf/091f75ad-91fd-4275-aa37-e17b31984b67(Accessed on September 20, 2019).
[20]
Bhaskaran, K.; Dos-Santos-Silva, I.; Leon, D.A.; Douglas, I.J.; Smeeth, L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3•6 million adults in the UK. Lancet Diabetes Endocrinol., 2018, 6(12), 944-953.
[http://dx.doi.org/10.1016/S2213-8587(18)30288-2] [PMID: 30389323]
[21]
Durrer Schutz, D.; Busetto, L.; Dicker, D.; Farpour-Lambert, N.; Pryke, R.; Toplak, H.; Widmer, D.; Yumuk, V.; Schutz, Y. European Practical and Patient-Centred guidelines for adults obesity management in primary care. Obes. Facts, 2019, 12(1), 40-66.
[http://dx.doi.org/10.1159/000496183] [PMID: 30673677]
[22]
Vidya, Narayanaswami Linda, P. Dwoski Obesity: Current and Potential Pharmacotherapeutics and Targets Pharmacol Ther., 2017, 170, 116-147.
[23]
Hill, J.O.; Wyatt, H.R.; Peters, J.C. Energy balance and obesity. Circulation, 2012, 126(1), 126-132.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.087213] [PMID: 22753534]
[24]
Yancy, W.S., Jr; Olsen, M.K.; Guyton, J.R.; Bakst, R.P.; Westman, E.C. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: A randomized, controlled trial. Ann. Intern. Med., 2004, 140(10), 769-777.
[http://dx.doi.org/10.7326/0003-4819-140-10-200405180-00006] [PMID: 15148063]
[25]
Boaz, M. Macronutrient composition in weight loss diets—A meta-analysis. J. Obes. Weight Loss Ther., 2015, 5, 3.
[26]
National Heart, Lung and Blood Institute (NHLBI) Obesity Education Initiative Expert Panel on the Identification, Evaluation and Treatment of Obesity in Adults. Clinical guide lines on the identification, evaluation, and treatment of over weightand obesity in adults: Executive summary. Am. J. Clin. Nutr., 1998, 68, 899-917.
[http://dx.doi.org/10.1093/ajcn/68.4.899]
[27]
Maclean, P.S.; Bergouignan, A.; Cornier, M.A.; Jackman, M.R. Biology’s response to dieting: the impetus for weight regain. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2011, 301(3), R581-R600.
[http://dx.doi.org/10.1152/ajpregu.00755.2010] [PMID: 21677272]
[28]
Coutinho, S.R.; Rehfeld, J.F.; Holst, J.J.; Kulseng, B.; Martins, C. Impact of weight loss achieved through a multidisciplinary intervention on appetite in patients with severe obesity. Am. J. Physiol. Endocrinol. Metab., 2018, 315(1), E91-E98.
[http://dx.doi.org/10.1152/ajpendo.00322.2017] [PMID: 29360396]
[29]
Polidori, D.; Sanghvi, A.; Seeley, R.J.; Hall, K.D. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity (Silver Spring), 2016, 24(11), 2289-2295.
[http://dx.doi.org/10.1002/oby.21653] [PMID: 27804272]
[30]
Koliaki, C.; Spinos, T.; Spinou, M.; Brinia, M.E.; Mitsopoulou, D.; Katsilambros, N. Defining the optimal dietary approach for safe, effective and sustainable weight loss in overweight and obese adults. Healthcare (Basel), 2018, 6(3), 73.
[http://dx.doi.org/10.3390/healthcare6030073] [PMID: 29958395]
[31]
FDA draft guidance. Guidance for Industry Developing Products for Weight Management. linee guida FDA, 2007.
[32]
Zhang, Z.Y.; Wang, M.W. Obesity, a health burden of a global nature. Acta Pharmacol. Sin., 2012, 33(2), 145-147.
[http://dx.doi.org/10.1038/aps.2011.185] [PMID: 22301854]
[33]
Roberts, C.A.; Christiansen, P.; Halford, J.C.G. Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? Acta Diabetol., 2017, 54(8), 715-725.
[http://dx.doi.org/10.1007/s00592-017-0994-x] [PMID: 28421338]
[34]
U.S. Preventive Services Task Force. Screening for obesity in adults: Recommendations and rationale. Ann. Intern. Med., 2003, 139(11), 930-932.
[http://dx.doi.org/10.7326/0003-4819-139-11-200312020-00012] [PMID: 14644896]
[35]
Welbourn, R.; Dixon, J.; Barth, J.H.; Finer, N.; Hughes, C.A.; le Roux, C.W.; Wass, J. Guidance Development Group. NICE-accredited commissioning guidance for weight assessment and management clinics: a model for a specialist multidisciplinary team approach for people with severe obesity. Obes. Surg., 2016, 26(3), 649-659.
[http://dx.doi.org/10.1007/s11695-015-2041-8] [PMID: 26738895]
[36]
Apovian, C.M.; Aronne, L.J.; Bessesen, D.H.; McDonnell, M.E.; Murad, M.H.; Pagotto, U.; Ryan, D.H.; Still, C.D. Endocrine Society. Pharmacological management of obesity: An endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2015, 100(2), 342-362.
[http://dx.doi.org/10.1210/jc.2014-3415] [PMID: 25590212]
[37]
Rodgers, R.J.; Tschöp, M.H.; Wilding, J.P. Anti-obesity drugs: past, present and future. Dis. Model. Mech., 2012, 5(5), 621-626.
[http://dx.doi.org/10.1242/dmm.009621] [PMID: 22915024]
[38]
Heal, D.J.; Gosden, J.; Smith, S.L. What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology, 2012, 63(1), 132-146.
[http://dx.doi.org/10.1016/j.neuropharm.2012.01.017] [PMID: 22313529]
[39]
McNeely, W.; Benfield, P. Orlistat. Drugs, 1998, 56(2), 241-249.
[http://dx.doi.org/10.2165/00003495-199856020-00007] [PMID: 9711448]
[40]
Torgerson, J.S.; Hauptman, J.; Boldrin, M.N.; Sjöström, L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 2004, 27(1), 155-161.
[http://dx.doi.org/10.2337/diacare.27.1.155] [PMID: 14693982]
[41]
Hauptman, J.; Lucas, C.; Boldrin, M.N.; Collins, H.; Segal, K.R. Orlistat in the long-term treatment of obesity in primary care settings. Arch. Fam. Med., 2000, 9(2), 160-167.
[http://dx.doi.org/10.1001/archfami.9.2.160] [PMID: 10693734]
[42]
Siebenhofer, A.; Horvath, K.; Jeitler, K.; Berghold, A.; Stich, A.K.; Matyas, E.; Pignitter, N.; Siering, U. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst. Rev., 2009, (3), CD007654.
[PMID: 19588440]
[43]
Padwal, R.S.; Majumdar, S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet, 2007, 369(9555), 71-77.
[http://dx.doi.org/10.1016/S0140-6736(07)60033-6] [PMID: 17208644]
[44]
Zhi, J.; Melia, A.T.; Funk, C.; Viger-Chougnet, A.; Hopfgartner, G.; Lausecker, B.; Wang, K.; Fulton, J.S.; Gabriel, L.; Mulligan, T.E. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J. Clin. Pharmacol., 1996, 36(11), 1006-1011.
[http://dx.doi.org/10.1177/009127009603601104] [PMID: 8973989]
[45]
Karamadoukis, L.; Shivashankar, G.H.; Ludeman, L.; Williams, A.J. An unusual complication of treatment with orlistat. Clin. Nephrol., 2009, 71(4), 430-432.
[http://dx.doi.org/10.5414/CNP71430] [PMID: 19356376]
[46]
Anderson, J.W. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin. Pharmacother., 2007, 8(11), 1733-1742.
[http://dx.doi.org/10.1517/14656566.8.11.1733] [PMID: 17685889]
[47]
Lam, D.D.; Przydzial, M.J.; Ridley, S.H.; Yeo, G.S.; Rochford, J.J.; O’Rahilly, S.; Heisler, L.K. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology, 2008, 149(3), 1323-1328.
[http://dx.doi.org/10.1210/en.2007-1321] [PMID: 18039773]
[48]
Halford, J.C.G.; Boyland, E.J.; Blundell, J.E.; Kirkham, T.C.; Harrold, J.A. Pharmacological management of appetite expression in obesity. Nat. Rev. Endocrinol., 2010, 6(5), 255-269.
[http://dx.doi.org/10.1038/nrendo.2010.19] [PMID: 20234354]
[49]
O’Neil, P.M.; Smith, S.R.; Weissman, N.J.; Fidler, M.C.; Sanchez, M.; Zhang, J.; Raether, B.; Anderson, C.M.; Shanahan, W.R. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. Obesity (Silver Spring), 2012, 20(7), 1426-1436.
[http://dx.doi.org/10.1038/oby.2012.66] [PMID: 22421927]
[50]
Smith, S.R.; Weissman, N.J.; Anderson, C.M.; Sanchez, M.; Chuang, E.; Stubbe, S.; Bays, H.; Shanahan, W.R. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med., 2010, 363(3), 245-256.
[http://dx.doi.org/10.1056/NEJMoa0909809] [PMID: 20647200]
[51]
Martin, C.K.; Redman, L.M.; Zhang, J.; Sanchez, M.; Anderson, C.M.; Smith, S.R.; Ravussin, E. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J. Clin. Endocrinol. Metab., 2011, 96(3), 837-845.
[http://dx.doi.org/10.1210/jc.2010-1848] [PMID: 21190985]
[52]
Gustafson, A.; King, C.; Rey, J.A. Lorcaserin (Belviq): A selective serotonin 5-HT2C agonist in the treatment of obesity. P&T, 2013, 38(9), 525-534.
[PMID: 24273398]
[53]
Fleming, J.W.; McClendon, K.S.; Riche, D.M. New obesity agents: Lorcaserin and phentermine/topiramate. Ann. Pharmacother., 2013, 47(7-8), 1007-1016.
[http://dx.doi.org/10.1345/aph.1R779] [PMID: 23800750]
[54]
Ben-Menachem, E.; Axelsen, M.; Johanson, E.H.; Stagge, A.; Smith, U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes. Res., 2003, 11(4), 556-562.
[http://dx.doi.org/10.1038/oby.2003.78] [PMID: 12690085]
[55]
Bray, G.A.; Hollander, P.; Klein, S.; Kushner, R.; Levy, B.; Fitchet, M.; Perry, B.H. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes. Res., 2003, 11(6), 722-733.
[http://dx.doi.org/10.1038/oby.2003.102] [PMID: 12805393]
[56]
Milano, W.; De Rosa, M.; Milano, L.; Riccio, A.; Sanseverino, B.; Capasso, A. The pharmacological options in the treatment of eating disorders. ISRN Pharmacol., 2013, 2013352865
[http://dx.doi.org/10.1155/2013/352865] [PMID: 23956871]
[57]
McElroy, S.L.; Hudson, J.I.; Capece, J.A.; Beyers, K.; Fisher, A.C.; Rosenthal, N.R. Topiramate binge eating disorder research group. topiramate for the treatment of binge eating disorder associated with obesity: A placebo-controlled study. Biol. Psychiatry, 2007, 61(9), 1039-1048.
[http://dx.doi.org/10.1016/j.biopsych.2006.08.008] [PMID: 17258690]
[58]
Monteiro, M.P. Obesity vaccines. Hum. Vaccin. Immunother., 2014, 10(4), 887-895.
[http://dx.doi.org/10.4161/hv.27537] [PMID: 24365968]
[59]
Gadde, K.M.; Allison, D.B.; Ryan, D.H.; Peterson, C.A.; Troupin, B.; Schwiers, M.L.; Day, W.W. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet, 2011, 377(9774), 1341-1352.
[http://dx.doi.org/10.1016/S0140-6736(11)60205-5] [PMID: 21481449]
[60]
Allison, D.B.; Gadde, K.M.; Garvey, W.T.; Peterson, C.A.; Schwiers, M.L.; Najarian, T.; Tam, P.Y.; Troupin, B.; Day, W.W. Controlled release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity (Silver Spring), 2012, 20(2), 330-342.
[http://dx.doi.org/10.1038/oby.2011.330] [PMID: 22051941]
[61]
Khera, R.; Murad, M.H.; Chandar, A.K.; Dulai, P.S.; Wang, Z.; Prokop, L.J.; Loomba, R.; Camilleri, M.; Singh, S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA, 2016, 315(22), 2424-2434.
[http://dx.doi.org/10.1001/jama.2016.7602] [PMID: 27299618]
[62]
Garvey, W.T.; Ryan, D.H.; Look, M.; Gadde, K.M.; Allison, D.B.; Peterson, C.A.; Schwiers, M.; Day, W.W.; Bowden, C.H. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. Am. J. Clin. Nutr., 2012, 95(2), 297-308.
[http://dx.doi.org/10.3945/ajcn.111.024927] [PMID: 22158731]
[63]
Colman, E.; Golden, J.; Roberts, M.; Egan, A.; Weaver, J.; Rosebraugh, C. The FDA’s assessment of two drugs for chronic weight management. N. Engl. J. Med., 2012, 367(17), 1577-1579.
[http://dx.doi.org/10.1056/NEJMp1211277] [PMID: 23050510]
[64]
Margulis, A.V.; Mitchell, A.A.; Gilboa, S.M.; Werler, M.M.; Mittleman, M.A.; Glynn, R.J.; Hernandez-Diaz, S. National birth defects prevention study. Use of topiramate in pregnancy and risk of oral clefts. Am. J. Obstet. Gynecol., 2012, 207(5), 405.e1-405.e7.
[http://dx.doi.org/10.1016/j.ajog.2012.07.008] [PMID: 22917484]
[65]
Lee, M.W.; Fujioka, K. Naltrexone for the treatment of obesity: Review and update. Expert Opin. Pharmacother., 2009, 10(11), 1841-1845.
[http://dx.doi.org/10.1517/14656560903048959] [PMID: 19537999]
[66]
Dwoskin, L.P.; Rauhut, A.S.; King-Pospisil, K.A.; Bardo, M.T. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev., 2006, 12(3-4), 178-207.
[http://dx.doi.org/10.1111/j.1527-3458.2006.00178.x] [PMID: 17227286]
[67]
Caixàs, A.; Albert, L.; Capel, I.; Rigla, M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des. Devel. Ther., 2014, 8, 1419-1427.
[http://dx.doi.org/10.2147/DDDT.S55587] [PMID: 25258511]
[68]
Wadden, T.A.; Foreyt, J.P.; Foster, G.D.; Hill, J.O.; Klein, S.; O’Neil, P.M.; Perri, M.G.; Pi-Sunyer, F.X.; Rock, C.L.; Erickson, J.S.; Maier, H.N.; Kim, D.D.; Dunayevich, E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring), 2011, 19(1), 110-120.
[http://dx.doi.org/10.1038/oby.2010.147] [PMID: 20559296]
[69]
Greenway, F.L.; Whitehouse, M.J.; Guttadauria, M.; Anderson, J.W.; Atkinson, R.L.; Fujioka, K.; Gadde, K.M.; Gupta, A.K.; O’Neil, P.; Schumacher, D.; Smith, D.; Dunayevich, E.; Tollefson, G.D.; Weber, E.; Cowley, M.A. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring), 2009, 17(1), 30-39.
[http://dx.doi.org/10.1038/oby.2008.461] [PMID: 18997675]
[70]
Billes, S.K.; Sinnayah, P.; Cowley, M.A. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol. Res., 2014, 84, 1-11.
[http://dx.doi.org/10.1016/j.phrs.2014.04.004] [PMID: 24754973]
[71]
Ornellas, T; Chavez, B. Naltrexone SR/Bupropion SR (Contrave). A new approach to weight loss in obese adults. Drug Forecast, 2011, 36(5), 255-262. 10.
[72]
Greenway, F.L.; Fujioka, K.; Plodkowski, R.A.; Mudaliar, S.; Guttadauria, M.; Erickson, J.; Kim, D.D.; Dunayevich, E. COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2010, 376(9741), 595-605.
[http://dx.doi.org/10.1016/S0140-6736(10)60888-4] [PMID: 20673995]
[73]
Hollander, P.; Gupta, A.K.; Plodkowski, R.; Greenway, F.; Bays, H.; Burns, C.; Klassen, P.; Fujioka, K. COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care, 2013, 36(12), 4022-4029.
[http://dx.doi.org/10.2337/dc13-0234] [PMID: 24144653]
[74]
Apovian, C.M.; Aronne, L.; Rubino, D.; Still, C.; Wyatt, H.; Burns, C.; Kim, D.; Dunayevich, E. COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring), 2013, 21(5), 935-943.
[http://dx.doi.org/10.1002/oby.20309] [PMID: 23408728]
[75]
Krieger, J.P.; Arnold, M.; Pettersen, K.G.; Lossel, P.; Langhans, W.; Lee, S.J. Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes, 2016, 65(1), 34-43.
[PMID: 26470787]
[76]
Katsurada, K.; Yada, T. Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J. Diabetes Investig., 2016, 7(Suppl. 1), 64-69.
[http://dx.doi.org/10.1111/jdi.12464] [PMID: 27186358]
[77]
Kanoski, S.E.; Rupprecht, L.E.; Fortin, S.M.; De Jonghe, B.C.; Hayes, M.R. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology, 2012, 62(5-6), 1916-1927.
[http://dx.doi.org/10.1016/j.neuropharm.2011.12.022] [PMID: 22227019]
[78]
Alhadeff, A.L.; Rupprecht, L.E.; Hayes, M.R. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology, 2012, 153(2), 647-658.
[http://dx.doi.org/10.1210/en.2011-1443] [PMID: 22128031]
[79]
Pi-Sunyer, X.; Obesity, S.; Prediabetes, I. SCALE obesity and prediabetes investigators. Liraglutide in weight management. N. Engl. J. Med., 2015, 373(18), 1781-1782.
[PMID: 26510028]
[80]
Inoue, K.; Maeda, N.; Kashine, S.; Fujishima, Y.; Kozawa, J.; Hiuge-Shimizu, A.; Okita, K.; Imagawa, A.; Funahashi, T.; Shimomura, I. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: A pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc. Diabetol., 2011, 10(10), 109.
[http://dx.doi.org/10.1186/1475-2840-10-109] [PMID: 22132774]
[81]
Horowitz, M.; Flint, A.; Jones, K.L.; Hindsberger, C.; Rasmussen, M.F.; Kapitza, C.; Doran, S.; Jax, T.; Zdravkovic, M.; Chapman, I.M. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res. Clin. Pract., 2012, 97(2), 258-266.
[http://dx.doi.org/10.1016/j.diabres.2012.02.016] [PMID: 22446097]
[82]
Yanovski, S.Z.; Yanovski, J.A. Long-term drug treatment for obesity: A systematic and clinical review. JAMA, 2014, 311(1), 74-86.
[http://dx.doi.org/10.1001/jama.2013.281361] [PMID: 24231879]
[83]
Daubresse, M.; Alexander, G.C. The uphill battle facing antiobesity drugs. Int. J. Obes., 2015, 39(3), 377-378.
[http://dx.doi.org/10.1038/ijo.2014.169] [PMID: 25214150]
[84]
Gadde, K.M.; Martin, C.K. Obesity pathophysiology and management. J. J. Am. Coll. Cardiol, 2018, 71(1), 69-84.
[85]
Li, Q.S.; Lenhard, J.M.; Zhan, Y.; Konvicka, K.; Athanasiou, M.C.; Strauss, R.S.; Francke, S. A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus. Pharmacogenet. Genomics, 2016, 26(2), 53-65.
[http://dx.doi.org/10.1097/FPC.0000000000000185] [PMID: 26524290]
[86]
Hauner, H.; Meier, M.; Jöckel, K.H.; Frey, U.H.; Siffert, W. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics, 2003, 13(8), 453-459.
[http://dx.doi.org/10.1097/00008571-200308000-00003] [PMID: 12893983]
[87]
Swinburn, B.A.; Sacks, G.; Hall, K.D.; McPherson, K.; Finegood, D.T.; Moodie, M.L.; Gortmaker, S.L. The global obesity pandemic: Shaped by global drivers and local environments. Lancet, 2011, 378(9793), 804-814.
[http://dx.doi.org/10.1016/S0140-6736(11)60813-1] [PMID: 21872749]